Use of combination therapy in IBD.
Kaplan
Gil
G
Inflammatory Bowel Disease Clinic, Division of Gastroenterology, Department of Medicine, University of Calgary, Alberta, Canada.
Panaccione
Remo
R
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D056747:Immunomodulation; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D012074:Remission Induction; D055502:Secondary Prevention; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents